In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Sometimes, people with hypocalcemia will also go on to develop certain neurological or psychological symptoms, including depression, confusion, memory loss ... calcium absorption or increase its loss ...